Filing Flows › Sight Sciences (SGHT) › Q3 2025
Sight Sciences (SGHT) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Sight Sciences (SGHT) reported revenue of $19.9M for the third quarter 2025 (Q3 2025), -1% from a year earlier and +2% from the quarter before. Operating margin was -39.7%, net loss $8.2M (41.0% of revenue).
Sight Sciences, Q3 2025: revenue $19.9M (-1% year over year), operating margin -39.7%, net loss $8.2M, operating cash flow −$8.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.9M | +2% | -1% |
| Operating profit | −$7.9M | — | — |
| Net earnings | −$8.2M | — | — |
| Operating cash flow | −$8.7M | — | — |
What changed
Revenue was $19.9M in Q3 2025, down 1% year over year and up 2% from the previous quarter. Surgical Glaucoma was the largest line at 99% of revenue. Dry Eye lost $1.3M year over year (down 88%), 533% of the total change.
Gross margin was 86.4%, up 2.5 points from a year earlier. Operating costs exceeded revenue by $7.9M, an operating margin of -39.7%. Operating expenses fell 11% while revenue fell 1%. The quarter ended with a net loss of $8.2M, narrower than the previous quarter's $11.9M loss.
Operating cash flow was −$8.7M. Non-cash charges added back $105K of depreciation and amortization and $2.4M of share-based compensation. Working capital and other items used $3.1M. Capital expenditures of $170K exceeded it, leaving free cash flow of −$8.9M.
Questions
What was Sight Sciences' revenue in the third quarter 2025?
Sight Sciences (SGHT) reported revenue of $19.9M for the third quarter 2025 (Q3 2025), -1% from a year earlier and +2% from the quarter before.
Was Sight Sciences profitable in the third quarter 2025?
Operating loss was $7.9M (-39.7% of revenue) and net loss $8.2M.
Source: Sight Sciences 10-Q on SEC EDGAR.